NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use of the NHS: Ipsen’s Cometriq (cabozantinib), Bayer’s Nexavar (sorafenib), and Eisai’s Lenvima (lenvatinib). The former two were previously only available via the Cancer Drugs Fund (CDF), and the latter sees approval after delays of more than two years.
NICE recommends thyroid cancer drug trio for NHS use
